New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma

NEW YORK, September 15, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Medtronic, Inc. (NYSE: MDT), Pharmacyclics Inc. (NASDAQ: PCYC) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6464-100free.

--
Johnson & Johnson Research Reports
On September 10, 2014, Johnson & Johnson's subsidiary Cordis Corporation (Cordis) announced the launch of INCRAFT AAA Stent Graft System (INCRAFT System) - an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from infrarenal abdominal aortic aneurysms (AAA). Available for use in Europe and Canada, the device offers a less invasive treatment approach for AAA which affects an estimated 24 million people worldwide. The new INCRAFT System comes with a 14 French (F) outer diameter, including the integrated sheath, which is equivalent to a 12F catheter sheath introducer profile. This compares to the most EVAR stent grafts which have a system profile ranging from 16F to 22F in size. Cordis stated that its ultra-low profile is designed for proximal and distal placement accuracy and allows for customization during the procedure to accommodate a wide range of anatomical sizes. The full research reports on Johnson & Johnson are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/JNJ/report.pdf

--
Merck & Co. Inc. Research Reports
On September 4, 2014, Merck & Co. Inc. (Merck) announced that the U.S. Food and Drug Administration (FDA) has granted an accelerated approval to its anti-PD-1 (programmed death receptor-1) therapy -KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Merck's KEYTRUDA is the first anti-PD-1 therapy approved in the U.S. and has received FDA's Breakthrough Therapy designation for advanced melanoma as it increases the ability of the body's immune system to fight the same. "KEYTRUDA embodies Merck's unwavering commitment to pursue breakthrough science to help people who are facing the most challenging diseases," said Kenneth C. Frazier, Chairman and CEO, Merck. The full research reports on Merck are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/MRK/report.pdf

--
Medtronic, Inc. Research Reports
On September 10, 2014, Medtronic, Inc. (Medtronic) announced the first U.S. implants in a study to evaluate the safety and effectiveness of the new Medtronic CoreValve®Evolut(TM) R System. Medtronic's investigational CoreValve Evolut(TM) R System offers new capabilities that are designed to advance deliverability and valve performance while providing the option to recapture and reposition the CoreValve Evolut R valve during deployment, if needed. The Company stated that its prospective CoreValve Evolut R Clinical Study will enroll up to 250 patients with severe symptomatic aortic stenosis who are considered at high or extreme risk for open-heart surgical aortic valve replacement, at up to 25 U.S. sites. Primary endpoints of the study are all-cause mortality and disabling stroke at 30 days, as well as device success rate at 24 hours to seven days, while secondary endpoints include recapture success rate, when attempted, and hemodynamic (blood flow) performance. The full research reports on Medtronic are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/MDT/report.pdf

--
Pharmacyclics Inc. Research Reports
On September 10, 2014, the stock of Pharmacyclics Inc. (Pharmacyclics) rallied 7.74% to close at $127.81. Shares in Pharmacyclics opened the session at $118.82, and fluctuated in the range of $118.15 - $129.16. A total of 3.04 million shares changed hands during the session, which was over three times the stock's 30-day daily average volume of 0.95 million. Over the last one month, the Company's stock has gained 7.08%, outperforming the S&P 500 index which rose 3.03% during the same period. Also, the stock closed above its 50-day and 200-day moving averages of $111.95 and $112.16, respectively. The full research reports on Pharmacyclics are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/PCYC/report.pdf

--
NPS Pharmaceuticals, Inc. Research Reports
On September 10, 2014, the stock of NPS Pharmaceuticals, Inc. (NPS) rallied 25.11% to end the trading session at $32.34 - the stock's highest since July 3, 2014. Shares in NPS opened the session at $30.50, and fluctuated in the range of $29.30 - $32.37, with a total of 10.71 million shares changing hands. The sharp rise in NPS' stock came after the Company reported that the U.S. FDA posted briefing materials for the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting scheduled for September 12, 2014, to review NPS's Biologics License Application (BLA) for Natpara® (rhPTH[1-84]). According to the Company, Natpara is a bioengineered replacement therapy for endogenous parathyroid hormone (PTH) that the Company has developed for the treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of PTH. NPS added that EMDAC's recommendation will be considered by the FDA in its review of the Company's BLA for Natpara. The Prescription Drug User Fee Act (PDUFA) date for completion of the review of the Natpara BLA is October 24, 2014. The full research reports on NPS Pharma are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/NPSP/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review